Video

What is the PSA Blood Test?

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of thumbnail.
What Patients With Genitourinary Cancers Should Know After ASCO 2025
Image of Dr. Deville.
What are the Long-Term Side Effects of Proton Therapy in Prostate Cancer?
Image of Doctor.
Long-Term Prostate Cancer Data Highlights Risk and Survivorship Needs
Image of Dr. Tagawa.
Breaking Down the Benefits of Clinical Trial Participation in Cancer Care
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Crafting an Individual Treatment Plan for Patients With Prostate Cancer
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
NeuroSAFE Increases Erectile Function After Prostate Cancer Surgery
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Xtandi and Talzenna Therapy Shows Responses in Advanced Prostate Cancer
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Better Understanding Genetic Mutations Influence in Cancer Care
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
An Expert Highlights His Key Takeaways From The 2025 ASCO GU Symposium
Image of man with black hair.
Personalized Medicine Makes Strides Across the GU Oncology Treatment Space
Related Content
Illuccix is now FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy: © stock.adobe.com.
June 23rd 2025

Illuccix is FDA Approved to Guide Radioligand Use in Prostate Cancer

Spencer Feldman
Illuccix is now FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer: © stock.adobe.com.
June 19th 2025

FDA Updates Talzenna-Xtandi Label for HRR-Mutated Metastatic Prostate Cancer

Spencer Feldman
FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.
June 7th 2025

Utilizing AI in Prostate Cancer Care and Management

Alex Biese
How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.
Image of bottle
June 6th 2025

Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation

Roman Fabbricatore
Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine.